Education
About Us
Working with TipRanks
Follow Us
Getinge AB (GNGBY)
OTHER OTC:GNGBY
Top Page
Getinge AB
(OTC:GNGBY)
Rating:72Outperform
Price Target:
$22.50
▲(3.54% Upside)
Getinge AB (GNGBY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.00B
Dividend Yield2.2%
Average Volume (3M)177.00
Price to Earnings (P/E)41.5
Beta (1Y)0.57
Revenue Growth9.03%
EPS Growth-40.47%
CountryUS
Employees11,827
SectorHealthcare
Sector Strength47
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.20
Shares Outstanding254,152,370
10 Day Avg. Volume132
30 Day Avg. Volume177
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit0.39
Enterprise Value/Ebitda1.01
Forecast
1Y Price Target
$22.50Price Target Upside3.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Getinge AB Business Overview & Revenue Model
Company DescriptionGetinge AB is a global medical technology company based in Sweden, specializing in products and solutions for healthcare and life sciences. The company operates in three primary sectors: Surgical Workflows, Critical Care, and Life Science. Getinge's core offerings include advanced surgical equipment, anesthesia machines, intensive care unit solutions, sterilization products, and biopharmaceutical manufacturing systems. With a strong focus on innovation and efficiency, Getinge aims to improve patient outcomes and streamline healthcare operations worldwide.
How the Company Makes MoneyGetinge AB generates revenue through several key streams, primarily by selling medical devices and equipment to hospitals, surgical centers, and pharmaceutical companies. The company earns money from the sale of surgical instruments, critical care equipment, and sterilization products. Additionally, Getinge offers maintenance and support services, which provide ongoing revenue through service contracts and spare parts sales. Strategic partnerships with healthcare providers and research institutions enhance its market presence and drive sales. The company's focus on innovation and developing cutting-edge technology, such as robotic-assisted surgical systems, also contributes to its revenue growth by capturing new market segments.
Getinge AB Earnings Call Summary
Earnings Call Date:Jul 18, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 21, 2025
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook with strong organic growth and improved margins, despite significant headwinds from tariffs and FX. Regulatory and quality improvements, along with successful strategic acquisitions, bolster the positive sentiment. However, challenges in the Life Science segment and market share losses in certain product categories are notable concerns.Q2-2025 Updates
Positive Updates
Solid Organic Growth
Net sales grew by 4.1% organically with positive development across all business areas and regions. Order intake increased by 4.4% organically, particularly strong in Acute Care Therapies and Surgical Workflows.
Improved Margins
Adjusted gross and EBITA margins improved due to acquisitions, price increases, and positive mix. The underlying EBITA margin would have been above 14% if not for tariffs and FX.
Strong Performance in Key Markets
Strong order intake in the U.S., China, and Germany, contributing positively to the overall performance.
Positive Regulatory and Quality Developments
Intra-aortic balloon catheter portfolio obtained EU MDR certificate. Positive trends in regulatory compliance and a decrease in field actions per million of net sales.
Paragonix Acquisition Success
Paragonix celebrated its 100th kidney transplant case and is trending ahead of expectations, contributing positively to group margins.
Negative Updates
Negative Impact of Tariffs and FX
Tariffs and currency negatively impacted the EBITA margin by minus 0.9 percentage points, with SEK 110 million cost from tariffs in Q2.
Challenges in Life Science Segment
Softer performance in Life Science due to high comps from the previous year.
Market Share Loss in ECMO and Balloon Pumps
Loss of market share due to restrictions on actively selling and marketing ECMO and balloon pump products.
Company Guidance
During the call, Getinge provided guidance for the fiscal year 2025, aiming for an organic net sales growth of 2% to 5% based on 2024 net sales. The company reiterated its financial targets for 2024 to 2028, which include achieving an average adjusted EPS growth of at least 12%. Key performance indicators showed positive trends, with recurring revenue now accounting for 65% of sales and high-margin products making up about two-thirds of sales. In the second quarter, organic net sales grew by 4.1%, and order intake increased by 4.4%. Despite challenges from tariffs and currency fluctuations, Getinge improved its adjusted EBITA margin to 12%, with an underlying performance suggesting it could have been above 14% without these headwinds. The company also highlighted its solid financial position, with leverage below 2.5x EBITDA.Getinge AB Financial Statement Overview
Summary
Getinge AB presents a mixed financial picture. The company demonstrates strong operational efficiency with healthy margins, but faces challenges with declining revenue growth and moderate profitability. The balance sheet is stable with conservative leverage, yet the declining ROE highlights potential issues in generating returns. Cash flow generation is improving, but conversion efficiency needs attention. Overall, while the company is financially stable, it must address growth and profitability challenges to enhance its financial health.Income Statement
Getinge AB's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) data indicates a decline in revenue growth rate by 18.8%, which is concerning. However, the company maintains a healthy gross profit margin of 46.9% and an EBIT margin of 10.8%, reflecting operational efficiency. The net profit margin is relatively low at 4.2%, indicating room for improvement in profitability. Overall, while the company has strong operational margins, the declining revenue growth is a significant concern.70
Positive
Balance Sheet
The balance sheet of Getinge AB is relatively strong with a debt-to-equity ratio of 0.39, indicating a conservative leverage position. The return on equity (ROE) is modest at 4.9%, suggesting moderate profitability relative to shareholder equity. The equity ratio stands at 51.1%, reflecting a solid equity base. While the company maintains a stable financial structure, the declining ROE over recent periods suggests potential challenges in generating returns.75
Positive
Cash Flow
Getinge AB's cash flow statement reveals a mixed outlook. The free cash flow growth rate is positive at 8.9% in the TTM period, indicating improved cash generation. However, the operating cash flow to net income ratio is low at 0.31, suggesting potential issues in converting income into cash. The free cash flow to net income ratio is 0.67, which is reasonable but indicates some inefficiencies. Overall, while cash flow generation is improving, the conversion efficiency remains a concern.65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.50B | 34.76B | 31.83B | 28.29B | 27.05B | 29.82B |
| Gross Profit | 16.64B | 16.15B | 14.49B | 13.41B | 13.58B | 14.72B |
| EBITDA | 6.37B | 5.31B | 5.91B | 5.70B | 6.15B | 7.20B |
| Net Income | 1.49B | 1.64B | 2.41B | 2.49B | 2.97B | 3.24B |
Balance Sheet | ||||||
| Total Assets | 56.37B | 63.92B | 53.59B | 52.03B | 44.55B | 45.01B |
| Cash, Cash Equivalents and Short-Term Investments | 1.95B | 2.96B | 2.73B | 5.68B | 4.08B | 6.06B |
| Total Debt | 11.17B | 10.73B | 8.08B | 5.82B | 4.31B | 10.21B |
| Total Liabilities | 27.35B | 30.71B | 23.18B | 21.58B | 19.38B | 23.53B |
| Stockholders Equity | 28.82B | 33.01B | 30.17B | 30.04B | 24.75B | 21.02B |
Cash Flow | ||||||
| Free Cash Flow | 2.70B | 3.27B | 1.60B | 2.23B | 5.63B | 6.15B |
| Operating Cash Flow | 4.03B | 4.58B | 2.96B | 3.37B | 6.56B | 7.20B |
| Investing Cash Flow | -5.85B | -4.55B | -6.54B | -1.47B | -1.33B | -1.99B |
| Financing Cash Flow | 1.50B | 504.00M | 511.00M | -500.00M | -7.24B | -297.00M |
Getinge AB Technical Analysis
Positive
21.73
Price Trends
20.35
Positive
19.88
Positive
19.03
Positive
Market Momentum
0.44
Negative
60.81
Neutral
69.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNGBY, the sentiment is Positive. The current price of 21.73 is above the 20-day moving average (MA) of 21.00, above the 50-day MA of 20.35, and above the 200-day MA of 19.03, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 60.81 is Neutral, neither overbought nor oversold. The STOCH value of 69.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNGBY.
Getinge AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $24.48B | 37.69 | 9.73% | 0.93% | 2.47% | 63.68% | |
78 Outperform | $47.71B | 55.23 | 15.71% | ― | -5.23% | -39.83% | |
74 Outperform | $21.30B | 26.13 | 6.52% | 0.91% | 4.11% | -14.43% | |
72 Outperform | $6.00B | 41.46 | 4.80% | 2.20% | 9.03% | -40.47% | |
68 Neutral | $29.85B | 53.47 | 22.83% | ― | 9.30% | -14.95% | |
56 Neutral | $26.41B | ― | -7.10% | 3.21% | -0.76% | -55.03% | |
51 Neutral | $7.81B | -0.22 | -40.01% | 2.29% | 21.48% | -2.11% |
* Healthcare Sector Average
Performance Comparison
GNGBY
Getinge AB
21.73
1.15
5.59%
DXCM
Dexcom
75.08
5.74
8.28%
EW
Edwards Lifesciences
81.23
11.27
16.11%
PHG
Koninklijke Philips
27.58
-1.68
-5.74%
STE
Steris
244.77
6.05
2.53%
ZBH
Zimmer Biomet Holdings
105.06
-9.34
-8.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.